NASDAQ
16.23USD
-0.91 (-5.31%)
We have scored 14 news catalysts on Dyne Therapeutics, Inc. (DYN) over the past 12 months. The biggest single-day move next to one of them came Oct 27, 2025, when DYN closed +41.2%: “Wall Street Breakfast Podcast: Novartis Puts $12B On The Table”. Coverage across the window leans positive (average ticker sentiment +0.54). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3B
P/E
—
EPS
—
Beta
1.08
52W range
11.92-27.305
Day range
16.18–17.08
Open
17.08
Prev close
17.14
Volume
2.6M
Avg volume
2.4M
Dividend
0.00
IPO
2020-09-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Dyne Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Dyne Therapeutics, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for DYN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
